[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100324438":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":19,"responsibleParty":37,"collaborators":7,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":7,"enrollmentInfo":50,"targetDuration":7,"studyType":53,"phases":7,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Mayo Clinic","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Damon Houghton, MD, MS","PRINCIPAL_INVESTIGATOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","507-266-6717","vteregistry@mayo.edu",{"name":18,"role":14,"phone":15,"phoneExt":7,"email":16},"Danielle Vlazny, P.A.-C., M.S.",[20],{"facility":5,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":28,"coordinates":29},"Point",[30,31],-92.4699,44.02163,{"lat":31,"lon":30},[34,36],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":35},"Houghton.Damon@mayo.edu",{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"type":11,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Damon E. Houghton","Principal Investigator","100324438","registry-of-patients-prescribed-anticoagulation-100324438",false,"NCT03504007","Registry of Patients Prescribed Anticoagulation","Standardized, Guidelines Directed But Patients Oriented Clinical Practice Prospectively Registered","STAGPOR","Inclusion Criteria:\n\n• VTE seen at Thrombophilia Clinic and treatment with anti-coagulant is started within 14 days of VTE diagnosis date.\n\nExclusion Criteria:\n\n* Patients already on anticoagulation for other reasons or enrolled into anticoagulation clinical trials.","ALL","18 Years",{"count":51,"type":52},10000,"ESTIMATED","OBSERVATIONAL","The Gonda Vascular Center- Thrombophilia Clinic at Mayo Clinic in Rochester, Minnesota utilizes a standardized, guideline-directed, yet patient-oriented approach for treating patients diagnosed with venous thromboembolism (VTE).This study is the ongoing registry of clinical practice with standardized approach to patient assessment and therapy. As most of registries it does not have any definite number of recruited subjects or the date of study completion but provides anticipated number of recruited subjects and the time of anticipated enrolment which was provided only because of formal requirement related to structure of ClinicalTrials.gov website. This number will be updated and upgraded as we continue this registry.\n\nThe rates of VTE recurrence, major bleeding, clinically relevant non-major bleeding (CRNMB) and survival in patients treated with anticoagulation for acute VTE are assessed during prospective observation. VTE cases include an acute deep vein thrombosis (DVT) of lower or upper extremities, splanchnic veins, gonadal, renal, cerebral veins thrombosis and pulmonary embolism (PE). Therapy includes the whole spectrum of FDA approved anticoagulants such as \"classic\" agents: warfarin and heparinoids and the newer direct oral anticoagulants (DOACs) such as rivaroxaban, dabigatran, apixaban, and edoxaban.",[56,57],"Acute Deep Vein Thrombosis","Acute Pulmonary Embolism",[59,60,61,62,63,64],"Deep Vein Thrombosis","Pulmonary Embolism","Apixaban","Rivaroxaban","Dabigatran","Edoxaban","2026-04-22",{"date":67,"type":68},"2026-04-27","ACTUAL",{"date":70,"type":68},"2013-03-01",{"date":72,"type":52},"2033-03",{"name":5,"class":6},1]